NEWS FROM THE FDA!

1.PEGINESATIDE A DRUG INDICATED FOR ANEMIA OF CHRONIC RENAL FAILURE HAS BEEN PULLED FROM THE MARKET BECAUSE OF 3 DEATHS FROM ANAPHYLACTIC SHOCK REPORTEDLY.

2.REGORAFENIB, APPROVED IN METASTATIC COLON CANCER, JUST GOT APPROVED BY THE FDA FOR REFRACTORY GIST TUMOR AFTER FAILURE OF GLEEVEC AND SUTENT.

"The most common adverse effects reported with regorafenib are weakness and fatigue, hand-foot syndrome, diarrhea, loss of appetite, high blood pressure, mouth sores, infection, changes in voice volume or quality, pain, weight loss, stomach pain, rash, fever, and nausea."

FROM MEDSCAPE:

-----------------------------------------------------------------------------------------------
IN OTHER NEWS,

18 MONTHS  ANDROGEN DEPRIVATION WAS COMPARBLE TO 36 MONTHS FOR SURVIVAL AFTER 77 MONTHS OF OBSERVATION WITH ABOUT 25% OF PATIENTS DYING FROM LOCALLY ADVANCED POOR PROGNOSIS PROSTATE CANCER. WITH POOR PROGNOSIS DEFINED AS PSA>20 AND GLEASON>7 ACCORDING TO CANADIAN RESEARCHERS!